COVID-19 in Brazil: the headlines should be about science
- 10 November 2020
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 396 (10265), 1803
- https://doi.org/10.1016/s0140-6736(20)32375-8
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19The New England Journal of Medicine, 2020
- Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19JAMA, 2020
- Completion of clinical trials in light of COVID-19The Lancet. Respiratory Medicine, 2020
- Less Survivable Cancers Taskforce calls for faster diagnosisPublished by Elsevier BV ,2020
- Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trialThe Lancet, 2020
- Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA TrialAmerican Heart Journal, 2020
- COVID-19 in Brazil: “So what?”The Lancet, 2020